Article Details

Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC

Retrieved on: 2025-06-02 17:15:54

Tags for this article:

Click the tags to see associated articles and topics

Lower-dose abiraterone offers viable alternative to standard-dose for mCRPC. View article details on hiswai:

Excerpt

... alternative for patients with metastatic castration-resistant prostate cancer (mCRPC), according to phase 3 data presented at the 2025 American ...

Article found on: www.urologytimes.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo